Indefinite Delivery Contract SPE2DU25D9392

The key information from the federal contract IDV award can be summarized as follows:

The Defense Logistics Agency (DLA) awarded a single-award Indefinite Delivery Contract (IDC) to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler, to provide a comprehensive range of pharmaceutical products and medical supplies to the Department of Defense (DoD). The $499,999,999 IDC, valid through November 2026, enables the DLA to issue firm fixed-price delivery orders for branded and generic prescription drugs, over-the-counter medications, biologics, and medical consumables to support the recurring medical supply needs of military healthcare facilities and veterans' medical centers worldwide. This contract covers a diverse portfolio of pharmaceutical products, including specialized medications such as Xolair, Trikafta, Keytruda, Botox, and Nucala, across various dosage forms and medical domains.

The original solicitation was for the DLA Troop Support Medical Supply Chain's Pharmaceutical Prime Vendor Global Program Generation V (PPV-G GEN V) contracts, which aim to establish multiple prime vendor contracts to provide worldwide pharmaceutical support to various DoD customers, including the Defense Health Agency, the United States Coast Guard, and the US Naval Fleet. The $30.3 billion acquisition is structured as an unrestricted, fully competitive, firm-fixed-price, requirements-type contract with a 30-month base period and three 30-month option periods. The awards will be made on a regional basis, with at least three different contractors selected across the North/EUCOM, West/PACOM, South/SOUTHCOM, and Fleet line items, to ensure resiliency and access to vital pharmaceuticals during contingencies or natural disasters.